<- Go Home

ChemoMetec A/S

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer. In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training. Further, it develops XcytoMatic 30 cell counter and Xcyto 5, a versatile cell analyzer. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerod, Denmark.

Market Cap

DKK 13.8B

Volume

43.1K

Cash and Equivalents

DKK 341.8M

EBITDA

DKK 247.7M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

DKK 465.5M

Profit Margin

93.93%

52 Week High

DKK 804.00

52 Week Low

DKK 367.00

Dividend

0.88%

Price / Book Value

20.44

Price / Earnings

73.86

Price / Tangible Book Value

26.46

Enterprise Value

DKK 13.4B

Enterprise Value / EBITDA

54.22

Operating Income

DKK 236.5M

Return on Equity

30.10%

Return on Assets

19.65

Cash and Short Term Investments

DKK 341.8M

Debt

DKK 6.4M

Equity

DKK 673.4M

Revenue

DKK 495.6M

Unlevered FCF

DKK 145.2M

Sector

Life Sciences Tools and Services

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches